Home About Program Sponsors Apply Online
Locations & Directions
Participating Companies
Contact Us
Tell A Collegue

For Sponsorship Packages Click Here
For more information please contact Guy Tessler (678) 274-9699 or guy@aiccse.org

US-Israel Neurotechnology Business Exchange
Innovations that shape the future of the industry.

Dates: May 6-7, 2013

Location: Charleston, South Carolina

Purpose: Israel has long been recognized as one of the world’s foremost centers of global innovation. Capitalizing on this leadership role, the American-Israel Chamber of Commerce has organized highly effective industry-specific “business exchange” matchmaker events since 1994. The purpose for this business exchange is to create a matchmaking opportunity where Israeli Neurotechnology companies, US customers, integrators and investors can be introduced to each other and explore potential synergies. This event will to provide:

  • Exposure to a wide range of unique technologies from Israel that target the projected needs of the US market.
  • Pre-arranged one-on-one meetings in order to foster joint venture R&D, investment, marketing alliances, and other forms of cooperation.
  • A forum for leading technology, operational, investment, and healthcare researchers and executives to network.

Neurotechnology Focus Areas:

  • Brain Disorders
    • Aging
    • Addiction
    • Brain Tumors
    • Epilepsy
    • Neurodegeneration
    • Mental Illness
    • Pain
    • Stroke
    • Traumatic Brain Injury
  • Novel Approaches
    • Diagnosis
      • Early Detection
      • Biomarkers
      • Neuroimaging
      • Epigenetics
      • Ultrasound
    • Treatment
      • Brain Angioplasty
      • Brain Stimulation
      • Interventional Radiology
      • Immunotherapy
      • Targets for Drug Development
    • Practice
      • Brain Training
      • Machine Brain Interface
      • Rehabilitation
      • Telemedicine

US Organizations:

Major pharma, diagnostic, and device companies: TEVA. Johnson & Johnson, NuPathe, Abbott Laboratories, Biogen Idec, EMD Serono, Merck, Pfizer, GSK, Eli Lilly, AstraZeneca, Roche, Elan, Medtronic, Stryker, St. Jude, Siemens, GE, Bayer, Beckton Dickinson, Life Technologies, Illumina, and more.

Southeast-based pharma, diagnostic, and device companies, healthcare providers, investors, clinical research organizations, and universities: ArunA Biomedical, NeuroScience Associates, Targacept, Neuronetics, Cenerx, MUSC, Clemson, USC School of Medicine, Palmetto Health Richland, Health Science South Carolina, Emory Healthcare, Roper St. Francis Healthcare, Greenville Hospital System, Duke, Georgia Tech, Shepherd Center, Blue Cross Blue Shield of SC, Target Health, Harlan Laboratories, Selah Genomics, and more.

Israeli Companies:

Israeli companies will be asked to send their request for participation, addressing their compatibility with Neuro technologies described above. Top prospects include: Attengo, BioControl, Bioness, NovoCure, Insightec, ElmindA, Varniel, Neurosonix, Curatronic, Lifewave, Alpha Omega, NeuroQuest, Neurotech, Brainsway, BrainsGate, BrainStorm, Perflow, Surgical Theater, NanoRetina, Regenera Pharma, Step of Mind, Novo Cure, and Cognifit.  For a full listing of Israeli companies and researchers, click here.

Modus Operandi:

This event differs from a typical industry show or investor conference in that the participation is based on a pre-event matching procedure.

  • With the help of industry experts, generate a draft list of emerging clinically focused neuro technologies that are of significant interest.
  • Identify a gross prospect list of Israeli emerging companies and researchers, and categorize according to the targeted focus areas.
  • Meet with Israeli companies and researchers during South Carolina Business & Technology Mission to Israel in December 2012.
  • Identify a target list of US and Southeast-based research institutions and companies which may include medical devices, diagnostics, pharma, health insurance, disease management, equipment/ infrastructure vendors, clinical research organizations, investors, and health systems that would have an interest in the targeted technologies.
  • US organizations are asked to identify technology areas of interest and to pre-select, from the prospect list, the emerging technology companies and researchers with whom they would like to meet at the event.
  • Israeli companies / researchers are requested to specify which major US organizations they would like to see, and are included on the prospect list presented to the US companies.
  • The top 15 Israeli companies / researchers that emerge through the pre-event matchmaking will give short presentations at the event to be followed by pre-arranged one-on-one meetings.
  • At the event, opportunity is given to arrange additional meetings.
  • Keynote presentations by top policy, clinical, and industry leaders and networking opportunities are woven in-between the presentations and one-on-one meetings.
  • A volunteer “facilitator” will be assigned to each Israeli company / researcher who will contact them prior to the event with Hebrew capability as needed. They will be present at the one-on-one meetings, and help establish a follow up process.


The United States remains one of the major hubs for innovation, development, and commercialization of new products for the diagnosis and treatment of brain disorders.  Companies working in this field have seen that the presence in the US is a critical step for success. The US is not only the largest market in the world for new pharmacological treatments, diagnostics, and medical devices, but also it is one of the main hubs to obtain capital and know-how.   
South Carolina, in particular, is a center for Neurotechnology leadership. MUSC has been ranked as 2nd in the country for attracting Neuroscience research funds, and Neuroscience is a research strength of the University of South Carolina and its branch campuses throughout the state. Clemson University also has available a novel facility to evaluate exposure of samples to neurotoxins.  South Carolina is home to innovative life science firms with keen interest in striking mutually beneficial business deals: Selah Genomics, a personalized medicine diagnostic specialist, operates two Clinical Genomics Centers in the state, and their laboratories, operating under the US CLIA regulations, can serve as launch sites of clinically significant molecular / genomic assays developed in Israel.  State investment has fostered growth in Neuroscience research and Neurotechnology through the SmartState endowed chair programs, placing key leaders in the Neuroscience field at institutions across the state. Great opportunities for Neurotechnology partnerships exist with innovative programs in Telepsychiatry and Telestroke, healthy senior living through the SeniorSmart Initiative and state-wide access to patient populations through the Health Sciences South Carolina (HSSC) program that partners SC’s leading health centers and universities. 
Israel is well position to assume a global leadership role in the emerging Neurotechnology industry with its innovation and proven track record in fields such as computer science, nanotechnology and brain research.  The country has a strong tradition of placing science and technology at the forefront of its economic development – helping Israel gain its reputation as the “Start Up Nation”.   Recognizing this opportunity, President Shimon Peres has envisioned an initiative to launch Israel on the journey to become the world leader in Neurotechnology.  At his request, McKinsey & Company conducted an analysis of the Israel brain research and technology landscape, and the report indicated that Israel uniquely positioned to develop leadership in two areas of brain communication: the Brain Machine Interface (BMI) and therapeutic neuro-stimulation devices.
The first Breakthrough Research And Innovation in Neurotechnology (B.R.A.I.N.) Prize is an international award granted in Israel to an individual, group or organization for a recent, practical breakthrough in the field of brain technology. The $1,000,000 prize will recognize a disruptive innovation that is on a path to commercialization with potential significant impact to humanity. The award will be used to support further development towards commercialization of the winning technology.  The European Commission has chosen the Human Brain Project, in which the Hebrew University of Jerusalem is participating, as one of two Future and Emerging Technologies Flagship topics. The enterprise will receive funding of 1.19 billion euros over the next decade.
Israel has long been recognized as one of the foremost centers of global innovation. Capitalizing on this leadership role, the American-Israel Chamber of Commerce (AICC) has organized highly effective industry-specific “business exchange” matchmaker events since 1994. We believe appropriately positioned Israeli companies can take advantage of these opportunities, and we’re seeking the right companies and researchers to participate in this novel AICC Business Exchange focused on the Cutting Edge of Neurotechnology. 

The purpose of the US-Israel Neurotechnology Business Exchange is to bring together future-facing Israeli technologies and larger, more established US companies and research institutions that are either already major players in Neurotechnology or wish to enter the market (including payers, providers, government and industry).  In many cases these companies would rather invest in or even acquire new technologies than risk developing them internally. 

Our Israeli Partners:

Israel Brain Technologies
Inspired by the vision of Israeli President Shimon Peres, Israel Brain Technologies (IBT) has embarked upon a mission to advance Israel’s neurotechnology industry and establish the country as the epicenter of global brain technology and research.  IBT, a non-profit organization, promotes multi-disciplinary research and development projects in Israel and collaboration between the Israeli and global brain research communities as well as the entrepreneurial and business ecosystems. IBT is initiating and coordinating activities that will bring together academia, industry and all other related parties in order to pave the way towards the development of a successful, world-leading neurotechnology industry in Israel.

BIRD Foundation
BIRD is an acronym for Israel-U.S. Binational Industrial Research and Development. The BIRD Foundation's mission is to stimulate, promote and support industrial R&D of mutual benefit to the U.S. and Israel. BIRD takes no equity in the joint projects and all services are free of charge. It was established by the U.S. and Israeli governments in 1977 to generate mutually beneficial cooperation between the private sectors of the U.S. and Israeli high tech industries, including start-ups and established organizations. BIRD provides both matchmaking services between U.S. and Israeli companies, as well as funding covering up to 50% of project development and product commercialization costs. BIRD supports approximately 20 projects annually, and the cumulative sales of products developed through BIRD projects have exceeded $8 billion. BIRD has selected Neurotechnology as a priority area of focus for 2013, and organized the Accelerating U.S.‐ Israel Neuroscience & Neurotechnology Collaborations conference in Washington, DC this past September.